Phreesia (PHR) to Release Quarterly Earnings on Wednesday

Phreesia (NYSE:PHR) is anticipated to release its earnings data after the market closes on Wednesday, March 12th. Analysts expect Phreesia to post earnings of ($0.19) per share and revenue of $108.93 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company’s revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.58) earnings per share. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Down 7.5 %

Shares of PHR opened at $21.90 on Tuesday. The company has a market capitalization of $1.27 billion, a P/E ratio of -14.89 and a beta of 1.03. Phreesia has a one year low of $17.07 and a one year high of $30.53. The business’s 50 day simple moving average is $27.38 and its 200-day simple moving average is $24.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Insider Buying and Selling

In other news, CFO Balaji Gandhi sold 28,759 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $30.00, for a total value of $862,770.00. Following the completion of the transaction, the chief financial officer now owns 116,174 shares of the company’s stock, valued at $3,485,220. The trade was a 19.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael Weintraub sold 20,565 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $25.04, for a total value of $514,947.60. Following the completion of the sale, the director now owns 242,827 shares of the company’s stock, valued at $6,080,388.08. This trade represents a 7.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 195,740 shares of company stock valued at $5,441,409 over the last ninety days. Insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PHR shares. KeyCorp boosted their price objective on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 8th. JMP Securities reiterated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Truist Financial increased their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Friday, January 10th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $31.15.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.